STMN1 and metastatic neoplasm: shRNAs [54], ribozime [17], [55] or small molecules [56] designed to counteract stathmin expression and/or activity could represent important tools in the next future but, in light of our findings, they should probably be used to target highly aggressive metastatic tumors.